CPA
KNSA icon

Capital Performance Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Capital Performance Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-116
Closed -$2.9K – 1481
2024
Q3 		$2.9K Buy
+116
New +$2.83K ﹤0.01% 1371

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital Performance Advisors's KNSA Position: Q4 2024 in Review

Capital Performance Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2024, closing a stake of 116 shares — an estimated $2.9K sold.

Capital Performance Advisors first reported a position in KNSA in Q3 2024 and held it in 1 quarter. The position peaked at $2.9K in Q3 2024. 160 funds tracked by Wall St. Rank hold KNSA as of Q4 2024.

  • Capital Performance Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 116 Kiniksa Pharmaceuticals shares in Q4 2024, an estimated $2.9K.
  • Capital Performance Advisors first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Kiniksa Pharmaceuticals position peaked at $2.9K in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.